Revenue up 45%, a three-of-four Financial Scorecard, and 94.52% of 20 analysts rating Buy — yet Eli Lilly trades just 3% below its all-time high at 41x earnings, and the average target of $1,229.19 implies only about 7% upside. Current price: $1,149.75.
Changes over time: restnvest does not surface a Changes Over Time breakdown for Eli Lilly in this period, so no discontinued, sustained, evolved, or new-product items are available from the 10-K analysis — the counts default to zero.
Eli Lilly competes in large, durable pharmaceutical markets — diabetes, oncology, immunology, and chronic disease management — where patent-protected medicines command premium pricing and recurring demand. Global expansion across North America, Europe, and Asia broadens the addressable base, while the breadth of the pipeline gives the company multiple shots at the next blockbuster therapy.
Eli Lilly converts patent-protected drug franchises into rapid, high-margin growth: trailing revenue of $72.3 billion at a 35% net profit margin, with annual revenue up roughly 45%. Return on assets of 20.7% reflects efficient use of the capital base — used here in place of return on equity, which at 107% is distorted by leverage. Patents, brand strength, and manufacturing scale protect pricing and make the franchise difficult to displace.
Y = price target. X = days remaining on call (negative = past expected hit window). Bubble size = Anachart Performance Score. Dashed vertical = the expected-hit boundary.
Chart shows 5 of 20 covering analysts. See all on Anachart →
Eli Lilly's business case is straightforward and strong. Revenue grew roughly 45% to $72 billion on a trailing basis, the net profit margin is 35%, and return on assets is 20.7% — a figure used here in place of return on equity, which at 107% is distorted by the company's leverage. The Financial Scorecard reads 3 of 4 strong, with only Debt Safety rated mixed as leverage with support. Analysts agree emphatically: 94.52% rate the stock Buy, with just a single Sell. Where the picture turns more nuanced is price. The stock trades only 3% below its all-time high and above its 200-day average, which restnvest scores as Euphoric Entry, and at roughly 41 times earnings it is priced for continued rapid growth. The average analyst target of $1,229.19 sits just 6.97% above the recent price — modest headroom for a stock this widely followed. Timing is 2 of 3 supportive, so the near-term backdrop is constructive, but the Stretch signal is already overheating. The reconciliation is not a disagreement about quality. The fundamentals, the valuation scorecard, and the analyst consensus all lean positive. The single recurring caution is that the stock has already climbed to meet the optimism — the upside that remains is what the market has not yet priced, and on the consensus numbers that is only single digits.
Dive deeper into the fundamentals
See Eli Lilly's full 6-stage analysis on restnvest →See the full analyst picture
See all 20 analyst price targets on Anachart →